Global Sustained Release Injectables Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Sustained Release Injectables Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
It is a preparation with better therapeutic effect by delaying drug release rate from the formulation and reducing drug absorption rate into the body.
Sustained Release Injectables report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Sustained Release Injectables market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Diabetes and Leukemia are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Sustained Release Injectables industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Sustained Release Injectables key companies include AntriaBio, Ascendis Pharma, AstraZeneca, Aurobindo, Avadel, Alkermes, Amylin Pharmaceuticals, Biomarin and Camurus, etc. AntriaBio, Ascendis Pharma, AstraZeneca are top 3 players and held % share in total in 2022.
Sustained Release Injectables can be divided into Microparticles, Implants and Gels,, etc. Microparticles is the mainstream product in the market, accounting for % share globally in 2022.
Sustained Release Injectables is widely used in various fields, such as Diabetes, Leukemia, Acromegaly and Ophthalmology, etc. Diabetes provides greatest supports to the Sustained Release Injectables industry development. In 2022, global % share of Sustained Release Injectables went into Diabetes filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sustained Release Injectables market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
AntriaBio
Ascendis Pharma
AstraZeneca
Aurobindo
Avadel
Alkermes
Amylin Pharmaceuticals
Biomarin
Camurus
Critical Pharmaceuticals
Durect
Eli Lilly
Enzon
Ipsen
InnoCore Pharmaceuticals
Janssen
Merck
NanOlogy
Novartis
Oakwood Laboratories/PharmaSophia
OctoPlus
Pacira
PhaseBio Pharmaceuticals
Recipharm AB
Roche
Sanofi
Taiwan Liposome Company (TLC)
Xbrane Biopharma
Livzon Pharm
Luye Pharma Group
Segment by Type
Microparticles
Implants
Gels
Diabetes
Leukemia
Acromegaly
Ophthalmology
CNS
Rheumatology
Oncology
Reproductive Health
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Sustained Release Injectables market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Sustained Release Injectables introduction, etc. Sustained Release Injectables Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Sustained Release Injectables market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Sustained Release Injectables report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Sustained Release Injectables market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Diabetes and Leukemia are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Sustained Release Injectables industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Sustained Release Injectables key companies include AntriaBio, Ascendis Pharma, AstraZeneca, Aurobindo, Avadel, Alkermes, Amylin Pharmaceuticals, Biomarin and Camurus, etc. AntriaBio, Ascendis Pharma, AstraZeneca are top 3 players and held % share in total in 2022.
Sustained Release Injectables can be divided into Microparticles, Implants and Gels,, etc. Microparticles is the mainstream product in the market, accounting for % share globally in 2022.
Sustained Release Injectables is widely used in various fields, such as Diabetes, Leukemia, Acromegaly and Ophthalmology, etc. Diabetes provides greatest supports to the Sustained Release Injectables industry development. In 2022, global % share of Sustained Release Injectables went into Diabetes filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sustained Release Injectables market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
AntriaBio
Ascendis Pharma
AstraZeneca
Aurobindo
Avadel
Alkermes
Amylin Pharmaceuticals
Biomarin
Camurus
Critical Pharmaceuticals
Durect
Eli Lilly
Enzon
Ipsen
InnoCore Pharmaceuticals
Janssen
Merck
NanOlogy
Novartis
Oakwood Laboratories/PharmaSophia
OctoPlus
Pacira
PhaseBio Pharmaceuticals
Recipharm AB
Roche
Sanofi
Taiwan Liposome Company (TLC)
Xbrane Biopharma
Livzon Pharm
Luye Pharma Group
Segment by Type
Microparticles
Implants
Gels
Segment by Application
Diabetes
Leukemia
Acromegaly
Ophthalmology
CNS
Rheumatology
Oncology
Reproductive Health
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Sustained Release Injectables market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Sustained Release Injectables introduction, etc. Sustained Release Injectables Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Sustained Release Injectables market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices